Biocon Ltd

Biocon Ltd

Biocon Limited announced that its partner, Duopharma Biotech Berhad, secured multiple insulin contracts valued over MYR 225 million from the Ministry of Health, Malaysia. Biocon's Malaysian subsidiary, Biocon Sdn. Bhd., will supply various insulin products including recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year agreement for human insulin (~MYR 155.27 million) and two 2-year agreements for insulin glargine (~MYR 18 million) and insulin aspart (~MYR 52.5 million). This reinforces Biocon's long-standing commitment and presence in Malaysia's diabetes care market.

Biocon Ltd

Biocon Ltd has issued a communication to its shareholders regarding the deduction of Tax at Source (TDS) on the final dividend recommended for the Financial Year 2025-26. The Board had recommended a final dividend of Re. 0.50 per equity share, which is subject to shareholder approval at the upcoming Annual General Meeting on August 06, 2026, with a record date of July 03, 2026. The company details the varying TDS rates based on shareholder categories and residential status and advises shareholders to update their details for accurate tax processing.